About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Anavex Life Sciences (NASDAQ: AVXL) Says Phase 2b/3 for ANAVEX2-73 Met Primary and Secondary Endpoints Reducing Cognative Decline in Patients with Early Alzheimer’s

Anavex Life Sciences Corp. (NASDAQ: AVXL) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development of innovative therapeutics to treat neurodegenerative disorders such as Alzheimer’s, Parkinson’s, Rett Syndrome and more. Shares of the biopharma company are rallying 38% through early trading on Friday, December 2, 2022. Over the past three months, Anavex Life Sciences has seen average daily volume of 1.04 million shares. However, volume of 35.27 million shares or dollar volume of around $428.53 million, has already exchanged hands through early trading.

Shares of Anavex Life Sciences are gaining after the company announced results from its Phase 2b/3 clinical trial of ANAVEX2-73 for the treatment of mild cognitive impairment (MCI) from early stages of Alzheimer’s disease. The clinical trial results showed the drug candidate met primary and key secondary endpoints, which were determined from meaningful improvements in cognitive function as measured by ADAS-Cog, ADCS-ADL, and CDR-SB. The company says the next step is to meet with the FDA to discuss the clinical data and work on commercialization.

ANAVEX2-73 is an orally-administered, small-molecule activator of the sigma-1 receptor, which has shown the capability of restoring neural cell homeostasis and promoting of neuroplasticity. The Phase 2b/3 trial was a randomized, double-blind, multicenter, placebo-controlled study that enrolled 509 patients for the treatment of early Alzheimer’s disease over the course of 48 weeks.

In the trial, patients that were treated with ANAVEX2-73 were 84% more likely to have improved cognitive abilities as measured by ADAS-Cog score change of -0.50 or better from the baseline to the end of treatment when compared to the placebo group. On average, patients who saw improvements while taking the drug candidate saw an average ASAS-Cog cognition score of -4.03 points. This shows ANAVEX2-73 was 167% more effective in improving cognitive abilities compared to the placebo group.

“People living with Alzheimer’s disease desperately need new therapies and I am truly impressed with the outcome of this study, which demonstrated reversal of cognitive decline,” said A/Professor Stephen Macfarlane, FRANZCP, Head of Clinical Services at the Dementia Centre, HammondCare and Principal Investigator. “These results complement and are consistent with findings from the previously completed Alzheimer’s disease Phase 2a ANAVEX®2-73 trial, which also demonstrated therapeutic effect on cognition and function. ANAVEX®2-73 might be a very much needed solution for many patients with Alzheimer’s disease.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Anavex Life Sciences (NASDAQ: AVXL) Says Phase 2b/3 for ANAVEX2-73 Met Primary and Secondary Endpoints Reducing Cognative Decline in Patients with Early Alzheimer’s appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.